IL-33 mast cell axis is central in LL-37 induced bladder inflammation and pain in a murine interstitial cystitis model. (October 2018)

• Record Type: Journal Article
• Authors: Martin Jensen, M.; Jia, Wanjian; Schults, Austin J.; Ye, Xiangyang; Prestwich, Glenn D.; Oottamasathien, Siam
• Is Part Of: Cytokine. Volume 110(2018)
• Page Start: 420
• Page End: 427
• Publication Date: 2018-10
• Subjects: Interstitial cystitis -- Painful bladder syndrome -- IL-33 -- Mast cell -- Bladder pain -- Inflammation; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2018.05.012
• Languages: English
• ISSNs: 1043-4666

Abstract

Graphical abstract: Highlights: Mast cells play a key role in IC/PBS & in our murine model of LL-37 induced cystitis. IL-33 appears to be a key cytokine in mast cell activation within the bladder. Mast cell deficient mice demonstrate diminished bladder inflammation and pain. IL-33 is upregulated in the bladder after LL-37 exposure. Targeting the IL-33 – mast cell axis may be promising for future therapeutics. Abstract: Interstitial cystitis (IC), also known as painful bladder syndrome (PBS), is a debilitating chronic condition that afflicts over 3 million women above the age of 18 in the U.S., and most patients fail to respond to current treatment options. Mast cells have previously been implicated as both a diagnostic and prognostic marker in IC/PBS. Patients with IC/PBS have been shown to have elevated levels of IL-33, a cytokine released in response to tissue insult, in their urine. We hypothesize that mast cell-mediated inflammation induced from IL-33 may play an important role in initiating pain and inflammation in IC/PBS. A human cathelicidin, LL-37, which is found at elevated levels in IC/PBS patients, was used to induce an IC/PBS-like state of inflammation and bladder pain in mast cell deficient C-kit (−/−) and wild type C57Bl/6 (WT) mice. Inflammation was quantified using myeloperoxidase (MPO) expression in bladder tissues measured via ELISA. Response rate to suprapubic stimulation from von Frey filaments was used to assess the relative pain and discomfort. Both types of mice increased IL-33 expression in response to LL-37 exposure. However, mast cell deficient mice demonstrated significantly lower levels of inflammation (p < 0.001) and reduced pain response (p < 0.001) compared to WT mice. These findings implicate an IL-33-mast cell dependent axis with a potential etiology of pain and inflammation in IC/PBS. Future therapeutics aimed at targeting the IL-33 - mast cell axis could potentially serve as useful targets for treating IC/PBS.